Deepti Aurora-Garg

Executive Director, Companion Diagnostics
Deepti Aurora-Garg
Deepti is the Executive Director of Companion Diagnostics at MSD, She has been focusing on development of predictive biomarkers in genomics and proteomics that would aid clinical trial enrollment in oncology, In her current role she is also focused on development of markers for resistance in IO therapies. Prior to Merck she held several positons in biotechnology companies developing screening tests for oncology,  infectious diseases and organ transplants. Deepti has a PhD in molecular Biology/Immunology from Indiana University and received her post doctoral training from Children's Hospital of Boston, a affiliate of Harvard Medical School.


February 19 2020, 11:20
 - 11:50
Utilising Genomic Technologies As Predictive Biomarkers In Drug Targets For Immunotherapy
February 20 2020, 12:20
 - 12:50
Panel Discussion: Integrating Novel Genomic Technologies And Markers Into Drug Development

Other Speakers